It has also been shown that PI3K/Akt/mTOR inhibitor treatments have minimal activity against advanced colorectal cancer with PIK3CA-mutations including E545K, M1043V and H1047R and that concomitant KRAS mutations frequently contribute to this resistance [47]. Here, PIK3CA is linked to colorectal cancer.